IRADIMED (IRMD) CEO-linked trust sells 7,500 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
IRADIMED CORP insider reporting person Roger E. Susi, who serves as CEO, President, Chairman and a 10% owner, reported indirect open-market sales of Common Stock through the Phillip Susi 2008 Dynasty Trust.
Across seven transactions on April 27–28, 2026, that trust sold a total of 7,500 shares at weighted average prices ranging from about $84 to $90 per share, leaving 2,197,905 shares held indirectly by that trust. Additional indirect holdings include 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust and 162,950 shares by the Roger E. Susi Revocable Trust as of April 27, 2026.
The filing notes that these sales were made under a Rule 10b5-1 trading plan adopted on November 5, 2025, indicating a pre-arranged program rather than discretionary timing. It also states that the reporting person disclaims beneficial ownership of the reported securities except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 7,500 shares ($657,709)
Net Sell
9 txns
Insider
Susi Roger E.
Role
CEO, President, Chairman
Sold
7,500 shs ($658K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 998 | $84.13 | $84K |
| Sale | Common Stock | 847 | $85.77 | $73K |
| Sale | Common Stock | 742 | $86.52 | $64K |
| Sale | Common Stock | 900 | $88.00 | $79K |
| Sale | Common Stock | 263 | $88.81 | $23K |
| Sale | Common Stock | 2,819 | $88.98 | $251K |
| Sale | Common Stock | 931 | $89.70 | $84K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 2,197,752 shares (Indirect, By Phillip Susi 2008 Dynasty Trust)
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. This transaction was executed in multiple trades at prices ranging from $88.47 to $89.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $89.54 to $90.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $83.75 to $84.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $85.20 to $86.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $86.21 to $87.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $87.65 to $88.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $88.66 to $88.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Key Figures
Shares sold: 7,500 shares
Sale prices: $84.13–$89.70/share
Post-sale holdings (Phillip Susi 2008 Dynasty Trust): 2,197,905 shares
+3 more
6 metrics
Shares sold
7,500 shares
Net open-market sales reported for April 27–28, 2026
Sale prices
$84.13–$89.70/share
Reported weighted average transaction prices
Post-sale holdings (Phillip Susi 2008 Dynasty Trust)
2,197,905 shares
Total shares following transactions on April 28, 2026
Holdings (Matthew Susi 2008 Dynasty Trust)
2,062,500 shares
Indirect holdings as of April 27, 2026
Holdings (Roger E. Susi Revocable Trust)
162,950 shares
Indirect holdings as of April 27, 2026
Rule 10b5-1 plan adoption date
November 5, 2025
Plan governing the reported sales
Key Terms
Rule 10b5-1 trading plan, open-market sale, weighted average sale price, beneficial ownership, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
beneficial ownership regulatory
"The reporting person disclaims beneficial ownership of these securities except to the extent..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"for purposes of Section 16 or for any other purpose."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What insider activity did IRADIMED CORP (IRMD) report in this Form 4?
IRADIMED CORP reported that a trust associated with CEO Roger E. Susi sold 7,500 shares of Common Stock in open-market transactions. These sales occurred on April 27–28, 2026 under a pre-arranged Rule 10b5-1 trading plan.
Were the IRADIMED (IRMD) insider sales made under a Rule 10b5-1 plan?
Yes. The Form 4 states the sales were effected under a Rule 10b5-1 trading plan adopted on November 5, 2025. Such plans schedule trades in advance, indicating the timing was pre-arranged rather than a spur-of-the-moment decision.
What other indirect IRADIMED (IRMD) holdings are reported for Roger E. Susi?
The filing reports 2,062,500 IRADIMED shares held indirectly by the Matthew Susi 2008 Dynasty Trust and 162,950 shares held indirectly by the Roger E. Susi Revocable Trust, in addition to the holdings of the Phillip Susi 2008 Dynasty Trust.